Skip to main content
Funded Studies

Robert Edward Drolet, PhD

Principal Scientist at Merck

Location: West Point, PA United States

Dr. Robert Drolet obtained his PhD in neuroscience from Michigan State University, where he identified compensatory mechanisms and a role for alpha-synuclein in dopamine-producing neurons in the pathogenesis of Parkinson’s disease (PD). He completed postdoctoral training in neuroscience at the Pittsburgh Institute for Neurological Disorders and is currently a principal scientist in the neuroscience department at Merck Research Laboratories. In his ten years at Merck, he has led a preclinical drug discovery programs in PD and other neurodegenerative disorders, shepherding compounds through various phases of the pipeline. His research focuses primarily on imaging-based biomarkers in neurodegenerative disease and cellular mechanisms responsible for clearing toxic protein aggregations. Ongoing research in his lab seeks to identify ways to monitor alpha-synuclein as a biomarker for PD progression, and to develop methods to inhibit its accumulation as a therapeutic approach for PD.

Associated Grants

  • Esya PD360: A Multi-parametric Platform for Establishing a Novel Lysosome-based Biomarker and Identifying Therapeutic Interventions for Parkinson’s Disease


  • Alpha-Synuclein PET Tracer Discovery


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.